Stereochemistry | ACHIRAL |
Molecular Formula | C26H24N6O2S2 |
Molecular Weight | 516.638 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=C(SC(=N1)C2=CC=CN=C2)C(=O)NC3=CC=CC=C3C4=CN5C(CN6CCOCC6)=CSC5=N4
InChI
InChIKey=LAMQVIQMVKWXOC-UHFFFAOYSA-N
InChI=1S/C26H24N6O2S2/c1-17-23(36-25(28-17)18-5-4-8-27-13-18)24(33)29-21-7-3-2-6-20(21)22-15-32-19(16-35-26(32)30-22)14-31-9-11-34-12-10-31/h2-8,13,15-16H,9-12,14H2,1H3,(H,29,33)
Molecular Formula | C26H24N6O2S2 |
Molecular Weight | 516.638 |
Charge | 0 |
Count |
MOL RATIO
1 MOL RATIO (average) |
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
SRT2104, also known as GSK2245840, is a novel, first in class, highly selective small molecule activator of the NAD + dependent deacetylase SIRT1. SIRT1 has been suggested as putative therapeutic target in multiple age-related diseases including type 2 diabetes and dyslipidemias. SRT2104 in the phase II of clinical trial to treat type 2 diabetes mellitus and psoriasis also in the phase I for its use in case of colitis. Also was reported, that we report that SRT2104, penetrated the blood-brain barrier, attenuated brain atrophy, improved motor function, and extended survival in a mouse model of Huntington's disease.
CNS Activity
Originator
Approval Year
Sourcing
PubMed
Patents
Sample Use Guides
oral administration (10–300 mg/kg/day; for five to 28 days)
Route of Administration:
Oral